HDAC9 and central nervous system cancer: Our previous studies have shown that combination of HDAC and proteasome inhibitors provided inhibition of glioma growth in vitro, and dramatic potentiation of cell killing that far exceeded the effects of either agent alone, although these studies incorporated non‐brain‐penetrant agents [17, 27].